Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers

Table 3

Hazard ratios and 95% confidence intervals derived from Cox regression for ER/PR/HER2 subtype and surrogate classification.

	Stage 1 (𝑛=59,182)	Stage 2 (𝑛=49,982)	Stage 3 (14,616)
ER/PR/HER2*
ER+/PR+/HER2−	1.00	1.00	1.00
ER+/PR+/HER2+	1.26 (1.04, 1.52)	1.24 (1.12, 1.37)	1.08 (0.94, 1.22)^†
ER+/PR−/HER2−	1.17 (0.96, 1.43)*	1.50 (1.35, 1.67)	1.66 (1.47, 1.89)
ER+/PR−/HER2+	1.39 (1.03, 1.88)	1.44 (1.25, 1.67)	1.25 (1.04, 1.50)
ER−/PR+/HER2−	1.96 (1.28, 3.02)	1.92 (1.51, 2.43)	1.83 (1.35, 2.48)
ER−/PR+/HER2+	2.21 (1.24, 3.93)	1.75 (1.28, 2.40)	1.65 (1.09, 2.50)
ER−/PR−/HER2−	2.26 (1.93, 2.64)	2.08 (1.92, 2.25)	2.84 (2.58, 3.12)
ER−/PR−/HER2+	1.89 (1.53, 2.31)	1.78 (1.61, 1.97)	1.92 (1.72, 2.34)
Immunohistochemical surrogates for molecular classification**
Luminal A	1.00	1.00	1.00
Luminal B, HER2−	3.02 (2.58, 3.54)	2.54 (2.33, 2.76)	2.22 (1.99, 2.47)
Luminal B, HER2+	2.02 (1.71, 2.38)	2.06 (1.88, 2.26)	1.66 (1.47, 1.87)
Triple negative	4.68 (4.06, 5.38)	3.93 (3.63, 4.26)	4.45 (4.02, 4.93)
HER2 overexpressing	3.98 (3.29, 4.83)	3.31 (2.99, 3.66)	3.02 (2.70, 3.39)

∗Adjusted for age, race/ethnicity, tumor grade, and socioeconomic status.
∗∗Adjusted for age, race/ethnicity, and socioeconomic status.
^†Confidence intervals that include 1.00 indicate that the risk of mortality within a stage for a subtype was no worse than the reference category.